↑ 疾患リストへ ← 戻る

 84. サルコイドーシス [臨床試験数:106,薬物数:161(DrugBank:74),標的遺伝子数:81,標的パスウェイ数:138] 

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04017936January 202011 November 2019Interleukin-1 Blockade for Treatment of Cardiac SarcoidosisInterleukin-1 Blockade for Treatment of Cardiac SarcoidosisCardiac SarcoidosisDrug: Anakinra;Drug: PlacebosVirginia Commonwealth UniversityAmerican Heart AssociationRecruiting21 YearsN/AAll28Phase 2United States
2NCT02523092December 201929 July 2019Use of CXCL9 as a Biomarker of Acthar EfficacyUse of CXCL9 as a Biomarker of Acthar EfficacySarcoidosisDrug: Acthar gelUniversity of California, San FranciscoMallinckrodtNot recruiting18 Years65 YearsAll14Phase 4United States
3NCT03814317November 201922 October 2019Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary HypertensionAn Open-Label Study of Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension and Interstitial Lung Disease (SAPPHIRE)Sarcoidosis;Precapillary Pulmonary Hypertension;Interstitial Lung DiseaseDrug: Inhaled TreprostinilUniversity of FloridaUnited TherapeuticsNot recruiting18 Years99 YearsAll10Phase 2United States
4NCT04064242October 18, 20197 October 2019Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisA Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary SarcoidosisPulmonary SarcoidosisDrug: CMK389;Drug: PlaceboNovartis PharmaceuticalsNot recruiting18 Years65 YearsAll66Phase 2
5NCT03942211September 27, 201916 September 2019A Study in Subjects With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral SelexipagA Multicenter, Randomized, Double-blind, Group-sequential, Placebo-controlled 52-week Period Followed by a 104-week, Single-arm, Open-label Period Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral SelexipagSarcoidosis-associated Pulmonary HypertensionDrug: Selexipag;Drug: PlaceboActelionNot recruiting18 Years75 YearsAll150Phase 2/Phase 3
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04109911September 25, 201914 October 2019Effect of Fermented Oyster Extract on Musculoskeletal Biomarkers in Relative Sarcopenia AdultsEffect of Fermented Oyster Extract on Musculoskeletal Biomarkers in Relative Sarcopenia Adults: a Randomized, Double-blinded, Placebo-controlled TrialMuscular SarcoidosisDietary Supplement: Fermented oyster extract;Dietary Supplement: PlaceboPusan National University Yangsan HospitalRecruiting50 YearsN/AAll54N/AKorea, Republic of
7NCT04020380September 6, 201930 September 2019Azithromycin a Treatment for Pulmonary SarcoidosisA Single Arm, Open-label Exploratory Clinical Trial of Azithromycin in Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: Azithromycin 250Mg CapsuleHull and East Yorkshire Hospitals NHS TrustRecruiting18 Years80 YearsAll30Phase 2United Kingdom
8NCT04008069September 3, 201916 September 2019Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisA Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent SarcoidosisSarcoidosisDrug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1;Drug: PlacebosStanford UniversityRecruiting18 Years80 YearsAll15Phase 2United States
9NCT03793439May 15, 20199 September 2019Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisTofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent SarcoidosisSarcoidosis, Pulmonary;Sarcoidosis Lung;SarcoidosisDrug: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial;Diagnostic Test: Spirometry;Genetic: RNA Sequencing;Diagnostic Test: Laboratory testing;Drug: Corticosteroid;Drug: Tofacitinib 5mg [Xeljanz] 1 year open-label extensionOregon Health and Science UniversityPfizerRecruiting18 Years89 YearsAll5Phase 1United States
10NCT03910543April 11, 201920 May 2019Open-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma AnnulareOpen-label Trial of Tofacitinib in Cutaneous Sarcoidosis and Granuloma AnnulareCutaneous Sarcoidosis;Granuloma AnnulareDrug: Tofacitinib 5 mg twice dailyYale UniversityPfizerRecruiting18 YearsN/AAll15N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02920710February 1, 201926 August 2019ACTHAR Therapy for Central Nervous System SarcoidosisACTHAR Therapy for Central Nervous System SarcoidosisSarcoidosisDrug: Repository Corticotropin InjectionThe Cleveland ClinicMallinckrodtRecruitingN/AN/AAll20Phase 4United States
12NCT03824392January 29, 201922 October 2019Study of Intravenous ATYR1923 for Pulmonary SarcoidosisA Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary SarcoidosisPulmonary SarcoidosisBiological: ATYR1923 1.0 mg/kg or placebo;Biological: ATYR1923 3.0 mg/kg or placebo;Biological: ATYR1923 5.0 mg/kg or placeboaTyr Pharma, Inc.Foundation for Sarcoidosis ResearchRecruiting18 Years70 YearsAll36Phase 1/Phase 2United States
13NCT03593759January 15, 201930 September 2019Cardiac Sarcoidosis Randomized TrialCardiac Sarcoidosis Multi-Center Randomized Controlled TrialCardiac Sarcoidosis;SarcoidosisDrug: Prednisone;Drug: MethotrexateOttawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR)Recruiting18 YearsN/AAll194Phase 3United States;Canada
14NCT03746847December 1, 201818 March 2019PET Imaging in Patients With Suspected Cardiac SarcoidosisSomatostatin Receptor Imaging in Patients With Suspected Cardiac SarcoidosisCardiac SarcoidosisDrug: Gallium-68 DOTATATEUniversity of PennsylvaniaAdvanced Accelerator ApplicationsNot recruiting18 YearsN/AAll20N/AUnited States
15NCT03602976August 20, 201826 August 2019Ursodeoxycholic Acid (UDCA) for Hepatic SarcoidosisA Single-center, Open Label, Cross-over Study on the Effects of Ursodeoxycholic Acid (UDCA) in Patients With Hepatic SarcoidosisHepatic Sarcoidosis, Elevated Alkaline PhosphataseDrug: Ursodeoxycholic AcidEthan WeinbergAmerican Association for the Study of Liver Diseases;Exalenz Bioscience LTD.Recruiting18 YearsN/AAll10Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT03549598July 20, 201827 August 2018d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosisd68Ga-DOTATATE PET/CT Assessment of Cardiac SarcoidosisCardiac SarcoidosisDrug: 68Ga-DOTATATE PET/CT;Drug: 18FDG PET/CT scan;Drug: 13NH3 PET/CT scanMayo ClinicRecruiting18 YearsN/AAll15Phase 4United States
17NCT03528070May 201811 June 2018A Clinical Study of Tranilast in the Treatment of SarcoidosisA Clinical Study of Tranilast in the Treatment of SarcoidosisSarcoidosisDrug: TranilastThe First Affiliated Hospital with Nanjing Medical UniversityNot recruiting18 YearsN/AAll56Early Phase 1
18NCT03320070January 24, 201811 November 2019Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary SarcoidosisA Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: repository corticotropin injection;Drug: PlaceboMallinckrodtRecruiting18 Years90 YearsAll100Phase 4United States
19NCT03324503December 8, 201715 July 2019A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary SarcoidosisA Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: Glucocorticoid (prednisone or prednisolone)CelgeneRecruiting18 Years65 YearsAll24N/AUnited States;Netherlands;United Kingdom
20NCT03260556September 27, 201716 December 2017Pirfenidone for Progressive Fibrotic SarcoidosisPirfenidone for Progressive Fibrotic SarcoidosisSarcoidosis, PulmonaryDrug: Pirfenidone;Drug: PlacebosUniversity of CincinnatiRoyal Brompton & Harefield NHS Foundation TrustRecruiting18 Years90 YearsAll60Phase 4United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT03103490August 2, 201725 February 201918F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or InflammationCardiac Sarcoidosis;Myocardial InflammationDrug: 18F-FSPGStanford UniversityGE HealthcareRecruiting18 YearsN/AAll20Phase 2United States
22EUCTR2016-003360-39-DE27/06/201728 February 2019Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosisSafety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis - ABASARCSteroid-refractory Sarcoidosis
MedDRA version: 20.0 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ORENCIA
Pharmaceutical Form: Solution for injection in pre-filled syringe
Universitätsklinikum FreiburgAuthorised Female: yes
Male: yes
30Phase 2Germany
23JPRN-UMIN0000259362017/06/122 April 2019Japanese AntibaCterial drug maNagemEnt for cardiac Sarcoidosis TrialCardiac sarcoidosiscombination therapy group:
Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg.
Antimicrobial agent; Clarithromycin start from 400mg/day for 24weeks. Doxycycline start 100mg/day for 22 weeks after 2 months of clarithromycin therapy.

Prednisolone; Predonisolone start from 30mg/day and continue same dose for one month. After one month, prednisolone decrease 25mg, 20mg, 15mg, 10mg every 2-4 weeks. Finally, maintenance dose of predonisolone is 7.5mg.
National cerebral and cardiovascular centerRecruiting20years-oldNot applicableMale and Female80Not selectedJapan
24NCT03402308June 1, 201711 June 2018Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a RCTEffect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a Randomized, Double-blinded, Placebo-controlled TrialMuscular SarcoidosisDietary Supplement: Schisandra chinensis extract;Dietary Supplement: PlaceboPusan National University Yangsan HospitalNot recruiting50 YearsN/AAll54N/AKorea, Republic of
25JPRN-jRCTs03118030101/05/20172 April 2019Antibacterial therapy for severe sarcoid uveitisStudy of antibacterial therapy for severe uveitis by sarcoidosisSevere uveitis by sarcoidosis
Other eyes and adnexal disease;Other eyes and adnexal disease
Ordinary steroid medication with Clarithromycin and minomycinHiroshi TakaseRecruiting2080Both10Phase 1-2None
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT03265405April 1, 20171 April 2019Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of SarcoidosisEfficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled TrialSarcoidosisDrug: Low dose prednisolone;Drug: Medium dose prednisolonePostgraduate Institute of Medical Education and ResearchRecruiting18 Years65 YearsAll86Phase 4India
27NCT03259282March 7, 201711 June 2018Gammaglobulins Level is Predictive Factor of Evolution in SarcoidosisGammaglobulins Level is Predictive Factor of Evolution in SarcoidosisSarcoidosisBiological: Analysis of gamma globulinRennes University HospitalNot recruitingN/AN/AAll78N/AFrance
28NCT03048097February 1, 20172 September 2019Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac SarcoidosisSarcoidosisDrug: Fluorodeoxyglucose;Drug: Rubidium;Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion ImagingYale UniversityNot recruiting18 YearsN/AAll15Early Phase 1United States
29JPRN-jRCTs04118011116/12/201610 September 2019Estimated by FDG PET/CT in Myocardial SarcoidosisOptimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - OMT-CS studyCardiac sarcoidosis
Cardiac sarcoidosis
After using PSL for 6 months, patients were classified by decreasing rate of TLG. If TLG is decreasing over 70%, PSL was prescribed 5mg/day for more 6 months. If TLG is decreasing under 70%, arm A: PSL was prescribed 30mg/day and diminishing PSL 5mg per month for more 6 months arm B: MTX (6mg/week) and folic acid (5mg/week) was prescribed for more 6 monthsToyoaki MuroharaRecruiting20ageNot applicableBoth50Phase 3none
30EUCTR2016-002160-14-NL22/11/201628 November 2016Octreotide PET/CT scan for the imaging of disease activity in neurologic and cardiac sarcoidosis.68Ga-DOTA-NOC PET/CT for the imaging of disease activity in neurologic and cardiac sarcoidosis. - SCAN-GO TrialSarcoidosis.;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Name: Gallium-68-DOTA-N-Octreotide
Product Code: Ga-68-DOTA-NOC
Pharmaceutical Form: Injection
INN or Proposed INN: Ga-68-DOTA-NOC
CAS Number: 1040397-47-4
Other descriptive name: DOTANOC
Concentration unit: MBq megabecquerel(s)
Concentration type: up to
Concentration number: 160-
St. Antonius HospitalAuthorisedFemale: yes
Male: yes
Phase 2Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31NCT02643732November 201616 December 2017Fatigue in Sarcoidosis - Treatment With MethylphenidateFatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using MethylphenidateSarcoidosis;FatigueDrug: Methylphenidate (overencapsulated);Drug: Placebo (Over-encapsulated tablet)University of East AngliaClinical Research and Trials Unit (Norfolk & Norwich University Hospital, UK)Recruiting18 YearsN/AAll30N/AUnited Kingdom
32EUCTR2016-001255-49-NL18/10/20161 October 2018Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosisA multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosisPulmonary sarcoidosis
MedDRA version: 20.0 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Code: ACZ885
Pharmaceutical Form: Solution for injection
INN or Proposed INN: canakinumab
CAS Number: 914613-48-2
Current Sponsor code: ACZ885
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Novartis Pharma Services AGAuthorisedFemale: yes
Male: yes
38Phase 2United States;Germany;Netherlands
33JPRN-UMIN0000229962016/10/0822 July 2019Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial SarcoidosisOptimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis - Optimal Medical Therapy in Myocardial SarcoidosisMyocardial sarcoidosismediacl therapy with methotrexate
medical therapy with steroid
The Department of Cardiology, Nagoya University Graduate School of MedicineRecruiting20years-old90years-oldMale and Female50Not selectedJapan
34EUCTR2016-001255-49-DE15/08/201628 August 2017Study of efficacy, safety and tolerability of ACZ885 (Canakinumab) in patients with pulmonary sarcoidosisA multiple-dose, subject- and investigator-blinded, placebo-controlled, parallel design study to assess the efficacy, safety, and tolerability of ACZ885 (canakinumab) in patients with pulmonary sarcoidosisPulmonary sarcoidosis
MedDRA version: 20.0 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Code: ACZ885
Pharmaceutical Form: Solution for injection
INN or Proposed INN: canakinumab
CAS Number: 914613-48-2
Current Sponsor code: ACZ885
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Novartis Pharma Services AGAuthorisedFemale: yes
Male: yes
38Phase 2United States;Netherlands;Germany
35EUCTR2016-000342-60-GB21/06/201628 February 2019Fatigue and Sarcoidosis: Treatment with MethylphenidateFatigue in Sarcoidosis - A feasibility study investigating the treatment of fatigue in stable sarcoidosis patients using methylphenidate - Fatigue in Sarcoidosis: Treatment with MethylphenidateSarcoidosis-associated fatigue (Patients with stable sarcoidosis and chronic fatigue)
MedDRA version: 20.1 Level: PT Classification code 10039486 Term: Sarcoidosis System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: Methylphenidate
Product Name: Methylphenidate 10mg tablets
Product Code: NA
Pharmaceutical Form: Tablet
INN or Proposed INN: Methylphenidate
CAS Number: 113-45-1
Current Sponsor code: None
Other descriptive name: None
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Norfolk and Norwich University HospitalNot Recruiting Female: yes
Male: yes
30Phase 2United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT02812849June 201616 December 2017Somatostatin Receptor Imaging in Cardiac SarcoidosisSomatostatin Receptor Imaging in Cardiac SarcoidosisCardiac SarcoidosisDrug: Cu-64 DOTATATERigshospitalet, DenmarkRecruiting18 YearsN/AAll60N/ADenmark
37NCT02298491May 201626 August 2019CNS Sarcoidosis and Acthar GelClinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar GelCNS SarcoidosisDrug: H.P. Acthar GelUniversity of Maryland, BaltimoreMallinckrodtNot recruitingN/AN/AAll4Phase 4United States
38NCT02824419May 201621 July 2016Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary SarcoidosisImaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary SarcoidosisPulmonary SarcoidosisDrug: Methionine;Drug: DOTANOCTurku University HospitalRecruiting18 YearsN/ABoth10Phase 2/Phase 3Finland
39EUCTR2015-001815-11-FI19/04/20162 May 2016PET imaging of pulmonary sarcoidosisImaging of active granulomas with [18F]FDG and selected inflammatory PET tracers in pulmonary sarcoidosisPulmonary sarcoidosis with active garnulomas in the lungs. The diagnosis is based on the clinical evidence or biopsy.
MedDRA version: 18.1 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: 18F-fluorodeoxyglucose
Product Code: FDG
Pharmaceutical Form: Infusion
INN or Proposed INN: FLUORINE (18F) FLUDEOXYGLUCOSE
CAS Number: 105851-17-0
Concentration unit: MBq megabecquerel(s)
Concentration type: range
Concentration number: 170-185
Product Name: C11-methionine
Pharmaceutical Form: Infusion
INN or Proposed INN: L-methionine
Other descriptive name: L-METHIONINE ([11C]METHYL)
Concentration unit: MBq megabecquerel(s)
Concentration type: range
Concentration number: 400-440
Product Name: 68Ga-DOTANOC
Pharmaceutical Form: Infusion
INN or Proposed INN: DOTANOC
Other descriptive name: DOTANOC
Concentration unit: MBq megabecquerel(s)
Concentration type: range
Concentration number: 170-185
Turku PET CentreAuthorisedFemale: yes
Male: yes
Finland
40NCT02725177March 201611 March 2019Ocular Sarcoidosis Open Label Trial of ACTHAR GelOcular Sarcoidosis Open Label Trial of ACTHAR GelOcular Sarcoidosis;Panuveitis;Anterior UveitisDrug: Repository Corticotropin Injection;Drug: Repository Corticotropin Injection -Treatment ExtensionThe Cleveland ClinicMallinckrodtRecruiting18 Years99 YearsAll20N/AUnited States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT02546388October 201517 September 2018Somatostatin Receptor Imaging in Patients With Suspected Cardiac SarcoidosisSomatostatin Receptor Imaging in Patients With Suspected Cardiac SarcoidosisSarcoidosisDrug: Indium-111 PentreotideMarcelo F. Di Carli, MD, FACCMallinckrodtNot recruiting18 Years90 YearsAll17N/AUnited States
42NCT02497079July 20153 August 2015Diagnostic Accuracy of Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA SamplesComparison of the Diagnostic Accuracy of Nested and Real-time Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples in Patients With Isolated Intrathoracic LymphadenopathyLymphadenopathy;Tuberculosis;SarcoidosisDevice: Nested PCR for formalin-fixed tissues;Device: Nested PCR for fresh tissues;Device: Real-time PCR for fresh tissuesPusan National University HospitalRecruiting18 YearsN/ABoth100N/AKorea, Republic of
43EUCTR2013-005333-21-NL30/06/201514 September 2015Study of efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosisA multiple-dose, double-blind, placebo-controlled, parallel study to assess the efficacy, safety and tolerability of ACZ885 (Canikumab) in patients with pulmonary sarcoidosisPulmonary sarcoidosis
MedDRA version: 17.1 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Trade Name: ILARIS
Product Name: Canakinumab
Product Code: ACZ885
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: Canakinumab
CAS Number: 914613-48-2
Current Sponsor code: ACZ885
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 150-
Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe
Route of administration of the placebo: Subcutaneous use
Novartis Pharma Services AGNot RecruitingFemale: yes
Male: yes
90United States;Netherlands
44EUCTR2014-002224-26-NL07/05/201510 July 2015Infliximab dosing based on blood concentrations in patients with sarcoidosis: smart dosingA new dosing strategy of infliximab versus standard dosing in patients with severe sarcoidosis: optimization of treatment - Concentration guided dosing of infliximab in sarcoidosisSarcoidosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Trade Name: Remicade
Product Name: Remicade
Pharmaceutical Form: Powder for concentrate for solution for injection/infusion
St. Antonius HospitalAuthorisedFemale: yes
Male: yes
Netherlands
45NCT02625558April 201514 December 2015Riociguat for Sarcoidosis Associated Pulmonary HypertensionA Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary HypertensionSarcoidosisDrug: Riociguat;Drug: PlaceboUniversity of CincinnatiRecruiting18 YearsN/ABoth60Phase 4United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT02348905March 201519 February 2015ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label TrialACTHAR Gel for Cutaneous Sarcoidosis: An Open Label TrialSarcoidosis;Cutaneous SarcoidosisDrug: ACTHAR Gel 40 units twice weekly;Drug: ACTHAR Gel 80 units twice weekly.Albany Medical CollegeNot recruiting18 YearsN/ABoth10Phase 2/Phase 3United States
47NCT02155803February 201519 February 2015ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot StudyACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot StudySarcoidosis;Hypercalcemia Due to SarcoidosisDrug: ACTHAR Gel (adrenocorticotropic hormone)Albany Medical CollegeNot recruiting18 YearsN/ABoth10Phase 2/Phase 3United States
48NCT02246023January 201525 April 2016Fractionated Versus Target-controlled Propofol Administration in BronchoscopyTarget-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial.Lung Cancer;Sarcoidosis;Interstitial PneumoniaDevice: Flexible bronchoscopy in moderate sedation;Device: Oxygen saturation;Device: Blood pressure;Device: Propofol dosage;Device: Recovery time after bronchoscopyDaniel FranzenB. Braun Melsungen AGNot recruiting18 Years85 YearsBoth78Phase 4Switzerland
49NCT02192489November 201410 October 2016A Phase 2 Study With CC-220 in Skin SarcoidosisA Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous SarcoidosisSarcoidosisDrug: CC-220 0.3 mg Daily;Drug: CC-220 0.6mg Daily;Drug: PlaceboCelgene CorporationNot recruiting18 YearsN/ABoth0Phase 2
50NCT02265874October 201416 December 2017Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot StudyNicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot StudySarcoidosisDrug: Habitrol;Drug: Placebo to HabitrolOhio State UniversityThe Cleveland ClinicRecruiting18 Years75 YearsAll60Phase 1/Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51EUCTR2013-005376-17-NL20/06/201414 March 2016Sandostatin therapy in sarcoidosisSandostatin therapy in sarcoidosis - SST in SASarcoidosis
MedDRA version: 16.1 Level: HLGT Classification code 10003816 Term: Autoimmune disorders System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Sandostatin LAR
Pharmaceutical Form: Powder and solvent for solution for injection
INN or Proposed INN: OCTREOTIDE
CAS Number: 83150-76-9
Current Sponsor code: SMS 201-995
Other descriptive name: octreotide LAR / Sandostatin LAR (LAR=long acting release)
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 20-30
Erasmus Medical CenterNot RecruitingFemale: yes
Male: yes
Netherlands
52NCT02188017June 201414 December 2015Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)Sarcoidosis;Pulmonary SarcoidosisDrug: Acthar gelUniversity of CincinnatiMallinckrodtRecruiting18 Years90 YearsBoth20Phase 4United States
53NCT01955824May 201419 February 2015A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible BronchoscopyA RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPYLung Cancer;Tuberculosis;Sarcoidosis;Interstitial Lung DiseaseDrug: 1% lignocaine;Drug: 2% lignocainePostgraduate Institute of Medical Education and ResearchNot recruiting12 Years80 YearsBoth500Phase 2/Phase 3India
54NCT02036970May 201414 January 2019Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIATA Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary HypertensionPulmonary Arterial Hypertension;Pulmonary Hypertension;Interstitial Lung Disease;Idiopathic Interstitial Pneumonia;Idiopathic Pulmonary Fibrosis;Sarcoidosis;Respiratory Bronchiolitis Associated Interstitial Lung Disease;Desquamative Interstitial Pneumonia;Cryptogenic Organizing Pneumonia;Acute Interstitial Pneumonitis;Idiopathic Lymphoid Interstitial Pneumonia;Idiopathic Pleuroparenchymal FibroelastosisDrug: Bardoxolone methyl;Drug: PlaceboReata Pharmaceuticals, Inc.Not recruiting18 Years75 YearsAll166Phase 2United Kingdom;Spain;United States;Germany
55JPRN-UMIN0000138312014/04/302 April 2019Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitationPulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT.inhaled ciclesonide (400maicrogram, twice daily, for three months)Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, JapanRecruiting20years-old80years-oldMale and Female40Not selectedJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56NCT01210677April 201419 February 2015Cardiac Sarcoidosis Response To Steroids TrialCArdiac Sarcoidosis Response TO steRoids (CASTOR) TrialCardiac Sarcoidosis;SarcoidosisDrug: PrednisoneOttawa Heart Institute Research CorporationNot recruiting18 YearsN/ABoth0Phase 4Canada
57NCT02024555March 201424 June 2019Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary SarcoidosisInvestigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled TrialSarcoidosis; Antimycobacterial TherapyDrug: Levofloxacin;Drug: Ethambutol;Drug: Azithromycin;Drug: Rifampin;Drug: PlaceboVanderbilt UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting18 YearsN/AAll97Phase 2United States
58NCT02039687January 201416 December 2017Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisA Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With SarcoidosisNeuropathy of SarcoidosisDrug: ARA 290;Other: PlaceboAraim Pharmaceuticals, Inc.Not recruiting18 Years70 YearsAll64Phase 2United States;Netherlands
59NCT02134717January 201416 December 2017Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis ImmunophenotypesAn Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With SarcoidosisSarcoidosisDrug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks;Procedure: Bronchoscopy with bronchoalveolar lavage;Procedure: venipunctures;Procedure: Skin biopsyKevin F. GibsonUniversity of PittsburghNot recruiting18 Years80 YearsAll3N/AUnited States
60EUCTR2013-003016-45-NL11/09/201310 July 2015study the safety and effects of different doses of ARA 290 administered subcutaneously on the corneal nerve fiber density and symptoms of neuropathic pain in sarcoidosis patients.A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis - DOSARAsmall fiber neuropathy;Therapeutic area: Body processes [G] - Biological Phenomena [G16]Product Name: ARA 290
Product Code: ARA 290
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: ARA 290
Current Sponsor code: ARA 290
Concentration unit: mg milligram(s)
Concentration type: range
Concentration number: 1-8
Pharmaceutical form of the placebo: Powder for solution for injection/infusion
Route of administration of the placebo: Subcutaneous use
Araim PharmaceuticalsNot RecruitingFemale: yes
Male: yes
64Phase 2United States;Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61EUCTR2013-000242-18-NL23/05/20133 June 2013Low dose dexamethasone in newly diagnosed sarcoidosisLow dose dexamethasone in newly diagnosed sarcoidosis - (DEXSAR) TrialPatients with newly diagnosed, pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Trade Name: Dexamethasone 0,5mg
Product Name: Dexamethasone
Pharmaceutical Form: Tablet
INN or Proposed INN: DEXAMETHASONE
CAS Number: 50-02-2
Current Sponsor code: Tiofarma
Other descriptive name: Dexamethasone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
AuthorisedFemale: yes
Male: yes
Netherlands
62NCT01830959April 201314 December 2015Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)SarcoidosisDrug: Roflumilast;Drug: PlaceboUniversity of CincinnatiThe Cleveland Clinic;University of Pittsburgh;University of Illinois at Chicago;Henry Ford Health System;Albany Medical CollegeNot recruiting18 Years70 YearsBoth50Phase 4United States
63NCT01732211March 201317 November 2015A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary SarcoidosisA Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Group, 20-week Safety, Tolerability, And Efficacy Study Of Pd 0360324 In Adult Subjects With Chronic Pulmonary SarcoidosisPulmonary SarcoidosisBiological: PD 0360324;Other: Normal Saline for injectionPfizerNot recruiting21 Years75 YearsBoth1Phase 2United States
64NCT01652417October 201214 March 2016Treatment of Renal Sarcoidosis by Methylprednisolone BolusRandomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal SarcoidosisRenal SarcoidosisDrug: methylprednisolone bolus IV 15 mg/kg/d for 3 days.Assistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/ABoth40N/AFrance
65NCT01687517October 20124 May 2015Efficacy and Safety of Influenza Vaccine During SarcoidosisDetermination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis.Sarcoidosis;Influenza VaccineDrug: Seasonal influenza vaccine available for the 2012-2013 vaccine campaignAssistance Publique - Hôpitaux de ParisNot recruiting18 Years65 YearsBoth190Phase 3France
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66NCT01648933July 201222 October 2018Perfusion Analysis Using Rubidium in Cardiac SarcoidosisPerfusion Analysis Using Rubidium in Cardiac SarcoidosisSarcoidosisRadiation: Rubidium PETAssistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/AAll53N/AFrance
67ChiCTR-IOR-150059532012-01-0118 April 2017The effects of corticosteroid treatment on asymptomatic sarcoidosisThe effects of corticosteroid treatment on asymptomatic sarcoidosisSarcoidosisCorticosteroid-treated group :prednisolone ;Placebo:Placebo;The First Affiliated Hospital, Guangzhou Medical UniversityNot Recruiting1876BothCorticosteroid-treated group :64;Placebo:63;Other
68EUCTR2011-003630-13-NL22/11/201114 July 2014Tracer for the imaging of disease activity in sarcoidosis in the lung99mTc labelled anti-TNF-alpha for the imaging of disease activity in pulmonary sarcoidosis - TISSPulmonary sarcoidosis
MedDRA version: 17.0 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: 99mTc-Infliximab
Product Code: not applicable
Pharmaceutical Form: Radiopharmaceutical precursor, solution
INN or Proposed INN: not applicable
CAS Number: not applicab
Current Sponsor code: not applicable
Other descriptive name: 99m technetium infliximab
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentration number: 370 -
Sint Antonius HospitalAuthorisedFemale: yes
Male: yes
Netherlands
69NCT01587001November 201116 December 2017The Effect of N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary SarcoidosisThe Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary SarcoidosisPulmonary SarcoidosisDietary Supplement: N-acetyl-cysteine;Drug: PlaceboNational Jewish HealthAmerican Thoracic SocietyNot recruiting18 Years80 YearsAll17N/AUnited States
70NCT01440192September 201112 March 2018Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary SarcoidosisA Phase 1B, Multi-Center, Open-Label, Single Dose Study to Evaluate the Safety of Intravenous Infusion of Human Placental-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis.SarcoidosisStage 2 Pulmonary Sarcoidosis;Stage 3 Pulmonary SarcoidosisBiological: PDA001 (cenplacel-L)Celularity IncorporatedNot recruiting18 Years75 YearsAll4Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT01324999March 201116 December 2017Tadalafil for Sarcoidosis Associated Pulmonary HypertensionTadalafil for Sarcoidosis Associated Pulmonary HypertensionPulmonary HypertensionDrug: TadalafilUniversity of North Carolina, Chapel HillEli Lilly and Company;United Therapeutics;University of CincinnatiNot recruiting18 YearsN/AAll12Phase 2/Phase 3United States
72JPRN-UMIN0000042672010/10/012 April 2019PET/CT finding of cardiac sarcoidosissarcoidosisGive heparin Na before 18F-FDG PET/CT in the diagnosis of cardial sarcoidosis.Tokushima University HospitalNot RecruitingNot applicableNot applicableMale and Female30Not selectedJapan
73NCT03621553July 1, 20107 October 2019Vitamin D Homeostasis in SarcoidosisVitamin D Homeostasis in SarcoidosisSarcoidosis;Vitamin D InsufficiencyDrug: Ergocalciferol;Drug: Placebo;Drug: Calcium Citrate with Vitamin D2University of Texas Southwestern Medical CenterRecruiting21 YearsN/AAll90Phase 4United States
74NCT01169038July 201019 October 2017Investigation of the Efficacy of Antibiotics on Pulmonary SarcoidosisInvestigation of the Efficacy of Antibiotics on Pulmonary SarcoidosisPulmonary Sarcoidosis;Lung FunctionDrug: levaquin; ethambutol; rifampin and azithromycin.Vanderbilt UniversityNot recruiting18 Years75 YearsAll15Phase 1United States
75JPRN-UMIN0000065332010/04/012 April 2019Detecting sympathetic denervation and regional myocardial inflammation using 11C-hydroxyephedrine (HED) PET/CT and 18F-fluorodeoxyglucose (FDG) PET/CT and their relationship with arrhythmia in patients with cardiac involvement sarcoidosis and assessment of therapeutic effectssarcoidosisAll patients with first diagnosis of cardiac sarcoidosis or without steroid treatment will undergo 11C HED PET/CT,18F FDG PET/CT, 15O-PET water, MIBG, 12 leads ECG, AECG , SAECG and echocardiogram (Echo) before starting corticosteroid therapy and repeat study at 4 weeks after starting corticosteroid therapy. These patients will also have reevaluation 6 to 12 month after the second evaluations.
Sarcoidosis without cardiac involvement will undergo steroid treatment will also repeat the same measurements 4 weeks after the treatment.
Cardiac sarcoidosis but will not have steroid treatment will also repeat the same measurements 12 months later. Sarcoidosis patients without steroid treatment will also repeat the same measurements 12 months later.
Cardiac sarcoidosis with steroid treatment.

Cardiac sarcoidosis without steroid treatment.
arcoidosis without cardiac involvement who will have steroid treatement.
Sarcoidosis without cardiac involvement who will not have steroid treatement.
Normal control.
Hokkaido University Graduate School of Medicine,RecruitingNot applicableNot applicableMale and Female50Not applicableJapan
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76NCT01074554February 201019 October 2017Trial of Antimycobacterial Therapy in SarcoidosisPhase I/II Study of the Effects of Antibiotics on Sarcoidosis PathogenesisSarcoidosisDrug: Antibiotic Regimen;Drug: Placebo RegimenVanderbilt UniversityNot recruiting18 YearsN/AAll30Phase 1/Phase 2United States
77EUCTR2009-010714-30-BE28/09/200911 August 2014A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients with SarcoidosisA Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic SarcoidosisChronic sarcoidosis
MedDRA version: 13.1 Level: PT Classification code 10039486 Term: Sarcoidosis System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Golimumab Liquid in prefilled syringe
Product Code: CNTO 148
Pharmaceutical Form: Solution for injection
INN or Proposed INN: golimumab
Current Sponsor code: CNTO 148
Other descriptive name: Human anti TNF-alpha monoclonal antibody
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Product Name: ustekinumab liquid in prefilled syringe
Product Code: CNTO1275
Pharmaceutical Form: Solution for injection
INN or Proposed INN: ustekinumab
Current Sponsor code: CNTO 1275
Other descriptive name: Human anti-IL 12/23 monoclonal antibody
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 90-
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the placebo: Subcutaneous use
Janssen Biologics B.V.Not RecruitingFemale: yes
Male: yes
180Phase 2France;United States;Belgium;Denmark;Germany;Norway;Netherlands;Italy;United Kingdom
78NCT00918554September 200919 February 2015Efficacy Study of Methotrexate to Treat Sarcoid-associated UveitisCorticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATESarcoid-associated Uveitis;Ocular Sarcoidosis;Macular EdemaDrug: Methotrexate;Drug: PlaceboAssistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/ABoth7Phase 4France
79NCT00855205July 200919 February 2015Rituximab for Pulmonary SarcoidosisRituximab as a Novel Therapy in Refractory Sarcoidosis: A Prospective Open-SarcoidosisDrug: RituximabUniversity of CincinnatiUniversity of ChicagoNot recruiting18 YearsN/ABoth10Phase 2United States
80NCT00731757May 200919 February 2015Efficacy Study of Humira in the Treatment of Cutaneous SarcoidosisA Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous SarcoidosisSarcoidosis;Cutaneous SarcoidosisDrug: HumiraWright State UniversityStanford UniversityNot recruiting18 YearsN/ABoth20Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
81NCT02200146March 200919 February 2015Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.Pulmonary SarcoidosisDrug: Prednisone;Drug: Hydroxychloroquine + PrednisoneUniversity of Milano BicoccaAgenzia Italiana del FarmacoNot recruiting18 Years70 YearsBoth94Phase 3Italy
82NCT01245036January 200919 February 2015Efficacy of Antituberculous Therapy in Management of SarcoidosisRifampicin and Isoniazid Along With Prednisolone Compared to Prednisolone Alone in Treatment of Sarcoidosis: a Pilot Randomized Controlled TrialSarcoidosis;TuberculosisDrug: Antituberculous therapy along with steroidsPostgraduate Institute of Medical Education and ResearchNot recruiting15 Years75 YearsBoth100N/AIndia
83NCT00828828December 200819 February 2015Antibody Response to Influenza Vaccine in Patients With SarcoidosisControlled Trial of Serologic Efficacy of Influenza Vaccine in Patients With SarcoidosisPulmonary SarcoidosisBiological: Influenza VaccineShahid Beheshti Medical UniversityNot recruiting20 Years60 YearsBoth49Phase 3Iran, Islamic Republic of
84NCT00794274November 200819 February 2015The Efficacy and Safety of CC-10004 in Chronic Cutaneous SarcoidosisThe Efficacy and Safety of CC-10004 in Chronic Cutaneous SarcoidosisSarcoidosis;Cutaneous SarcoidosisDrug: CC-100004University of CincinnatiCelgene Corporation;Medical University of South CarolinaNot recruiting18 Years80 YearsBoth15Phase 2/Phase 3United States
85NCT00851929November 200820 August 2018Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary HypertensionAmbrisentan (Letairis) for Sarcoidosis Associated Pulmonary HypertensionSarcoidosis;Pulmonary HypertensionDrug: AmbrisentanMedical University of South CarolinaGilead SciencesNot recruiting18 Years99 YearsAll16Phase 2/Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
86NCT00739960August 200819 February 2015Safety Study of Abatacept to Treat Refractory SarcoidosisSarcoidosis, Trial of Abatacept in Refractory Disease (STAR). A Prospective Open-Label Trial of Abatacept in Progressive SarcoidosisSarcoidosisDrug: AbataceptUniversity of ChicagoBristol-Myers SquibbNot recruiting18 YearsN/ABoth1Phase 2United States
87NCT00701207July 200819 February 2015Study of Nicotine Patches in Patients With SarcoidosisModulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine ReceptorsPulmonary SarcoidosisDrug: nicotine patchElliott Crouser MDAmerican Thoracic SocietyNot recruiting18 YearsN/ABoth64Phase 4United States
88EUCTR2008-001340-39-IT30/06/200819 March 2012Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSASHydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSASPulmonary SarcoidosisTrade Name: PLAQUENIL*25CPR RIV 200MG
Pharmaceutical Form: Coated tablet
INN or Proposed INN: Hydroxychloroquine
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 200-
Trade Name: DELTACORTENE*10CPR 25MG
Pharmaceutical Form: Tablet
INN or Proposed INN: Prednisone
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 25-
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCAAuthorisedFemale: yes
Male: yes
Italy
89EUCTR2007-005117-18-AT03/04/200819 March 2012Safety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACSafety and efficacy study of bosentan in progressive pulmonary sarcoidosis - BOPSACProgressive pulmonary sarcoidosis
MedDRA version: 9.1 Level: PT Classification code 10037430 Term: Pulmonary sarcoidosis
Trade Name: Tracleer
Product Name: Bosentan
Pharmaceutical Form: Coated tablet
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
Medical University of Vienna, Department of Clinical PharmacologyNot RecruitingFemale: yes
Male: yes
Austria
90NCT00581607April 200819 February 2015Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionDouble Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary HypertensionSarcoidosis;Pulmonary Arterial HypertensionDrug: Bosentan;Drug: PlaceboUniversity of CincinnatiActelionNot recruiting18 YearsN/ABoth43Phase 2/Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
91NCT00555347October 20078 June 2015Use of Armodafinil for Fatigue in SarcoidosisUse of Armodafinil (R-modafinil) for Fatigue in SarcoidosisSarcoidosis;Fatigue;SleepinessDrug: Armodafinil;Drug: PlaceboUniversity of CincinnatiCephalonNot recruiting18 YearsN/ABoth20Phase 2/Phase 3United States
92NCT00690911August 200716 December 2017Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous SarcoidosisA Phase II, Multi-Center, Open Label Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis (HUM 04-36)SarcoidosisDrug: adalimumabWake Forest UniversityNot recruiting18 YearsN/AAll0Phase 2United States
93EUCTR2006-005361-19-GB09/03/200719 March 2012Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosisEvaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment of Pulmonary Hypertension secondary to sarcoidosisPulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstructive Pulmonary disease and Sarcoid. Once developed it may go on to cause right heart failure and severe breathlessness and eventually death. We believe that the use of bosentan may lower the pulmonary hypertension and improve symptoms.
MedDRA version: 8.1 Level: LLT Classification code 10037400 Term: Pulmonary hypertension
Trade Name: Tracleer
Product Name: tracleer
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Bosentan monohydrate
CAS Number: 147536978
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 62.5mg-125mg
St Georges HospitalAuthorisedFemale: yes
Male: yes
45United Kingdom
94NCT00403650November 200619 February 2015Inhaled Iloprost for Sarcoidosis-associated Pulmonary HypertensionInhaled Iloprost for Sarcoidosis Associated Pulmonary HypertensionSarcoidosis;Pulmonary Arterial HypertensionDrug: IloprostUniversity of CincinnatiNot recruiting18 Years90 YearsBoth20Phase 4United States
95NCT00274352September 200619 February 2015A Study of Adalimumab to Treat Sarcoidosis of the SkinA Double-Blind, Randomized, Placebo-Controlled Study of Adalimumab in the Treatment of Cutaneous SarcoidosisSarcoidosisDrug: adalimumabPariser, Robert J., M.D.Abbott;Virginia Clinical Research, Inc.Not recruiting18 Years89 YearsBoth16Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
96NCT00361387June 200619 February 2015Use of Focalin for Fatigue in SarcoidosisRandomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects.SarcoidosisDrug: d-methylphenidateUniversity of CincinnatiNot recruiting18 YearsN/ABoth12Phase 4United States
97EUCTR2006-001816-56-DK11/05/20063 April 2017Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLETCan PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? - KOMPLETsarcoidosisTrade Name: Humira
Product Name: Humira
Pharmaceutical Form: Injection*
RigshospitaletAuthorisedFemale: yes
Male: yes
10Phase 2Denmark
98NCT00311246April 200619 February 2015Trial of Adalimumab in Progressive SarcoidosisA Prospective Open-Label Trial of Adalimumab in Progressive SarcoidosisSarcoidosisDrug: AdalimumabUniversity of ChicagoAbbottNot recruiting18 Years85 YearsBoth11Phase 2United States
99NCT00279708January 200616 December 2017Atorvastatin to Treat Pulmonary SarcoidosisAtorvastatin as a Disease Modifying Agent in Stage II and III Pulmonary Sarcoidosis: A Randomized, Double-Blind, Placebo-Controlled TrialSarcoidosis, PulmonaryDrug: Atorvastatin;Other: Placebo Oral TabletNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting18 Years70 YearsAll55Phase 2United States
100NCT00402623January 200616 December 2017The Effect of Quercetin in SarcoidosisThe Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in SarcoidosisSarcoidosisDietary Supplement: quercetin;Other: placeboMaastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentNot recruitingN/AN/AAll18N/ANetherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
101NCT00305552February 200519 February 2015SARCOTHAL. Thalidomide in Skin SarcoidosisRandomized Controlled Trial of Thalidomide vs Placebo in Skin SarcoidosisSarcoidosisDrug: THALIDOMIDEAssistance Publique - Hôpitaux de ParisNot recruiting18 YearsN/ABoth40Phase 3France
102NCT00282438December 200316 December 2017Hematopoietic Stem Cell Support in Patients With Refractory SarcoidosisHematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II TrialSarcoidosisBiological: Autologous hematopoietic stem cell transplantation;Biological: Allogeneic stem cell transplantationNorthwestern UniversityNot recruiting18 Years60 YearsAll2Phase 1/Phase 2United States
103NCT00073437October 200319 February 2015A Study of Infliximab in Patients With SarcoidosisA Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade?) in Subjects With Chronic Sarcoidosis With Pulmonary Involvement.SarcoidosisDrug: InfliximabCentocor, Inc.Not recruiting18 YearsN/ABoth139Phase 3United States;Austria;Belgium;France;Germany;Netherlands;Sweden;Switzerland;United Kingdom;Italy
104NCT00262132September 200325 June 2018Mycophenolate for Pulmonary SarcoidosisMycophenolate for Pulmonary SarcoidosisPulmonary SarcoidosisDrug: MycophenolateMedical University of South CarolinaHoffmann-La RocheNot recruiting18 YearsN/AAll20Phase 3United States
105NCT00001877February 199919 February 2015Treatment of Pulmonary Sarcoidosis With PentoxifyllineTreatment of Pulmonary Sarcoidosis With PentoxifyllinePulmonary SarcoidosisDrug: PentoxifyllineNational Heart, Lung, and Blood Institute (NHLBI)Not recruitingN/AN/ABoth100Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
106NCT00000596June 197819 February 2015Diffuse Fibrotic Lung DiseaseLung Diseases;Pulmonary Fibrosis;SarcoidosisDrug: prednisone;Drug: cyclophosphamide;Drug: dapsoneNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting18 YearsN/ABothPhase 2

先頭へ